Gynecology strain | Vaginal candidiasis
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
1,2,3,4) 1 billion CFU
Also available as API
FUNCTIONALITY
Vaginal health • Inhibition of Candida strains • Treatment of vulvovaginal candidiasis (VVC)
Scientific support
Human clinical trials
1) Presidio Ospedaliero Delmati, Divisione di Ostetricia – Ginecologia. LF5 – LAB: studio di tollerabilità locale e di attività in pazienti affette da Candida albicans. 1992.
2) Centro di ricerca: USSL Lombardia 55 – Presidio Ospedaliero Delmati, S. Angelo Lodigiano, Divisione di Ostetricia-Ginecologia, Primario: Dott. Francesco Rovere. LF5 (lAB): Studio di dose range finding in pazienti affette da Candida albicans. 1992.
3) Donini G. Studio clinico sull’efficacia e la tollerabilità di LF5 (LAB) capsule vaginali in confronto a placebo in pazienti affette da Candida Albicans. Ospedale S. Salvatore, Divisione Ostetrico-Ginecologica, Pesaro. 1992. 4) Rovere F. Local tolerability and activity study in patients suffering from Candida albicans (“Delmati2 Hospital, Italy, 1992).
In vitro studies
a) Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol, Vol 50, Supp. 2, November/December 2016.
b) Deidda F. et al. In Vitro Activity of Lactobacillus fermentum LF5 Against Different Candida Species and Gardnerella vaginalis A New Perspective to Approach Mixed Vaginal Infections? J Clin Gastroenterol Volume 50, Supp. 2, November/December 2016.
